In 2023, the final year of our Third Medium-Term Management Plan, we achieved further growth in the four global prescription drug products in our pharmaceutical business. Moreover, when it comes to creating new value, we recorded major achievements: FDA approval of a new indication of REXULTI for the treatment of agitation associated with dementia due to Alzheimer’s disease, which is considered to be a serious social issue worldwide; and FDA approval of our renal denervation system, a new medical engineering technology for addressing hypertension.
In our nutraceutical business, functional beverages and supplements performed well, driven by consumers’ heightened awareness of health. We also grew our business in women’s health, a priority theme, with the participation of a newly acquired company in North America.
Meanwhile, we made steady progress on our 2050 Environmental Vision, Net Zero, which guides our efforts to reduce the total environmental impact of all our business activities to zero.
This year marks the start of our Fourth Medium-Term Management Plan. Under the plan, we will reinvest the proceeds of our business success to date, aiming to deliver a new phase of future growth even beyond the five-year plan period.
Guided by our commitment to total healthcare, the Otsuka group’s business is very closely related to well-being—in other words, people’s health and happiness. Amidst social, political, and economic change, we will continue to promote well-being in a way that only Otsuka can, and in so doing, live up to our corporate philosophy, Otsuka-people creating new products for better health worldwide.
We look forward to your continued support.
President and Representative Director, CEO